Genomic Data Set For RWE Applications - Global Strategic Business Report 2026: Capitalize On 16% CAGR And $1.5B In Total Revenue By 2032 With Illumina, Caris Life Sciences And Datavant


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 18, 2026 (GLOBE NEWSWIRE) -- "Genomic Data Set for Real World Evidence (RWE) Applications - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global genomic data sets for Real-World Evidence (RWE) applications market was valued at US$533.3 million in 2025 and is projected to reach US$1.5 billion by 2032, expanding at a compound annual growth rate (CAGR) of 16.0%. Market growth is being supported by advances in genomic sequencing, precision medicine, artificial intelligence, cloud infrastructure and the integration of genomic and longitudinal clinical data.

Genomic Data Is Reshaping Real-World Evidence Generation

Genomic data sets are transforming evidence generation across life sciences by providing a biologically anchored foundation for clinical research, regulatory decision-making and healthcare strategy. The integration of genomic profiles with electronic health records, insurance claims, patient registries and longitudinal health information enables more precise analysis of disease etiology, treatment response, adverse events and disease progression.

Biopharmaceutical companies, research institutions and healthcare organizations are increasingly using linked genomic and phenotypic data to identify biomarkers, stratify patient populations and support targeted therapy development. Major population-based resources, including the UK Biobank, the All of Us Research Program and Genomics England, are expanding the availability of data for observational research. These capabilities are strengthening regulatory submissions, reimbursement strategies and clinical decision-making, particularly in oncology, rare diseases and pharmacogenomics.

Technology and Infrastructure Advances Support Market Expansion

High-throughput sequencing platforms, including whole-genome, whole-exome and targeted sequencing technologies, are central to the development of genomic RWE applications. Privacy-preserving record linkage, cloud-based data environments and genomic data warehouses allow organizations to integrate and analyze complex clinical and molecular information at scale.

Cloud partnerships involving AWS, Google Cloud and Microsoft Azure are supporting secure, scalable genomic analytics. Artificial intelligence and bioinformatics platforms are also accelerating genotype-phenotype analysis, population-specific variant interpretation and multi-omic evidence generation. Federated learning is gaining adoption by enabling collaborative research without transferring sensitive genomic data outside protected institutional environments.

Interoperability standards, including FHIR Genomics and genomic extensions to the OMOP Common Data Model, are improving data consistency across electronic health records, clinical trials and observational studies. Consent management and data governance frameworks remain essential as healthcare organizations expand the secondary use of genomic information.

Adoption Across Healthcare and Life Sciences

Pharmaceutical companies are applying genomic RWE to clinical trial design, patient recruitment, adaptive trial models, post-market surveillance and drug repurposing. Payers are evaluating genomic evidence for value-based agreements, coverage policies and formulary management, especially in high-cost therapeutic areas.

Hospitals and health systems are incorporating genomic information into clinical decision support to improve diagnosis and personalize treatment pathways. Regulators, including the U.S. Food and Drug Administration and the European Medicines Agency, are increasingly considering genomically informed RWE for supplemental approvals, label expansions and benefit-risk assessments. Academic and public health organizations are also using genomic data to investigate gene-environment interactions, health disparities, infectious disease mutations and vaccine effectiveness.

Principal Genomic RWE Market Growth Drivers

  • Declining genomic sequencing costs and the expansion of large, diverse patient cohorts.
  • Growing adoption of precision medicine and value-based healthcare models.
  • Increasing regulatory acceptance of RWE for approvals and post-market monitoring.
  • Expansion of biobanks and national genomics programs linked to longitudinal health records.
  • Rising payer demand for genomics-informed utilization and reimbursement decisions.
  • Development of interoperable data standards and consent-based data-sharing frameworks.
  • Greater use of artificial intelligence for multi-omic analysis and evidence generation.
  • Strategic partnerships among technology companies, health systems and life sciences organizations.

Market Segmentation and Geographic Coverage

The report analyzes the genomic data sets for RWE applications market by value in US dollars. Data types covered include genetic DNA data, transcriptome RNA data, proteome protein data and metabolite data. Applications include oncology, cardiovascular disease, neurology, immunology and other therapeutic areas. End-use analysis covers biopharmaceutical organizations and other end users.

Geographic coverage includes the United States, Canada, Japan, China and Europe, including France, Germany, Italy, the United Kingdom, Spain, Russia and the rest of Europe. The analysis also covers Asia-Pacific, Latin America, the Middle East and Africa, with country-level insights for major markets.

Key Market Findings

  • The genetic DNA data segment is forecast to reach US$677.9 million by 2032, growing at a CAGR of 18.2%.
  • The transcriptome RNA data segment is projected to expand at a CAGR of 13.7% during the analysis period.
  • The U.S. market was valued at US$145.3 million in 2025.
  • China is forecast to grow at a CAGR of 21.1%, reaching US$342.0 million by 2032.
  • Additional growth opportunities are assessed across Japan, Canada, Germany and the broader Asia-Pacific region.

Report Benefits and Features

  • Independent annual sales analysis and market forecasts from 2025 through 2032.
  • Detailed assessment of market trends, growth drivers, restraints and emerging opportunities.
  • Regional and segment-level analysis designed to support strategic planning.
  • Competitive intelligence covering leading participants and their geographic presence.
  • Company profiles and analysis of organizations influencing the genomic RWE ecosystem.
  • Actionable insights for identifying revenue opportunities, investment priorities and market-entry strategies.
  • Complimentary report updates for one year.

Companies Featured

Companies covered include 23andMe, Aetion Inc., BC Platforms, Caris Life Sciences, Cegedim Health Data, Citeline, Clarify Health, Cognizant, ConcertAI, Cytel Inc., Datavant, Epigene Labs, Flatiron Health, Foundation Medicine Inc., Genuity Science, Guardant Health, HealthVerity Inc., Helix, iCarbonX and Illumina Inc.

Domain Expert Insights

The analysis incorporates perspectives from experts across industry, enterprise and academia to provide context beyond conventional secondary research. The report tracks early market signals emerging from expert discussions, company activity, conference sessions, keynote presentations, panel discussions, corporate disclosures, annual reports and institutional publications.

These intelligence sources are validated and synthesized to identify strategic market direction, competitive developments and emerging growth opportunities. The report also extends beyond market-level analysis to examine the companies shaping the competitive environment. Where analytically relevant, market share is assessed by major region to reflect differences in geographic structure, adoption patterns and competitive dynamics.

Strategic Questions Addressed

  • How will the global genomic data sets for RWE applications market evolve through 2032?
  • Which technology, regulatory and healthcare trends will have the greatest market impact?
  • Which data types, applications and end-use segments offer the strongest growth potential?
  • How will regional and segment market positions change during the forecast period?
  • Which companies are leading the market, and how are their competitive prospects developing?

Key Attributes

Report Attribute Details
No. of Pages 381
Forecast Period 2025-2032
Estimated Market Value (USD) in 2025 $533.3 Million
Forecasted Market Value (USD) by 2032 $1500 Million
Compound Annual Growth Rate 16%
Regions Covered Global


For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN18112026004107003653ID1111984011


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search